Rosuvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myocardial Ischaemia
Conditions
Myocardial Ischaemia, Coronary Artery Disease
Trial Timeline
Dec 1, 2001 → Dec 1, 2002
NCT ID
NCT00657527About Rosuvastatin
Rosuvastatin is a phase 3 stage product being developed by AstraZeneca for Myocardial Ischaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00657527. Target conditions include Myocardial Ischaemia, Coronary Artery Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00160745 | Phase 2 | Completed |
| NCT04846231 | Phase 2 | Completed |
| NCT02561845 | Pre-clinical | Withdrawn |
| NCT02484027 | Approved | UNKNOWN |
| NCT02077257 | Approved | UNKNOWN |
| NCT01837823 | Phase 2 | Completed |
| NCT01490398 | Approved | Completed |
| NCT01364220 | Phase 3 | Terminated |
| NCT00815659 | Approved | Completed |
| NCT00747149 | Approved | Completed |
| NCT00473655 | Approved | Completed |
| NCT00335699 | Approved | Completed |
| NCT00184951 | Phase 2 | Completed |
| NCT00240305 | Phase 3 | Completed |
| NCT00176332 | Phase 2 | Completed |
| NCT00228514 | Phase 3 | Completed |
| NCT00240266 | Phase 3 | Completed |
| NCT00241488 | Phase 3 | Completed |
| NCT00660764 | Pre-clinical | Completed |
| NCT00239681 | Phase 3 | Terminated |
Competing Products
20 competing products in Myocardial Ischaemia